Translational pediatrics · 2026
Sodium bicarbonate therapy for metabolic acidosis in children stratified by acute kidney injury status and chloride levels: a retrospective cohort study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Meng Xiangying, Qiu Conglian, Huang He, Hong Yi, Xiao Rongzhou, Han Meilin, Bai Zhenjiang, Xu Yuanyuan, Liu Huaqing, Wu Shuiyan
Аннотация
BACKGROUND: The efficacy of sodium bicarbonate in treating metabolic acidosis remains debated. Prior research indicated potential benefits for hyperchloremic patients and those with acute kidney injury (AKI). This study explored its effectiveness in children with or without AKI at diverse baseline chloride levels.
METHODS: A retrospective cohort of children with metabolic acidosis was selected from the Paediatric Intensive Care (PIC) database. Intensive care unit (ICU)-related data on diagnosis, laboratory tests, treatment, and outcomes were retrieved. Sub-grouping was done based on AKI status and baseline chloride levels. In-hospital and 28-day mortality were compared between children receiving and not receiving sodium bicarbonate, with adjustment for confounding factors.
RESULTS: Sodium bicarbonate therapy did not decrease in-hospital or 28-day mortality in overall AKI or in overall non-AKI children. Among stage 2-3 AKI [pediatric reference change value optimized for AKI (pROCK)] children, those on therapy had lower in-hospital (19.43% vs. 35.40%, P=0.002) and 28-day (17.43% vs. 32.74%, P=0.002) mortality, but this was not significant after adjustment. Stratification by baseline chloride level revealed a divergent association: when chloride was ≥113 mmol/L, sodium bicarbonate therapy was associated with lower mortality in both AKI and non-AKI children; conversely, when chloride was <107 mmol/L, it was associated with increased mortality.
CONCLUSIONS: The association between sodium bicarbonate therapy and mortality in children with metabolic acidosis critically depends on baseline chloride levels. Its use was associated with increased mortality in those with hypochloremia (chloride <107 mmol/L) but reduced mortality in those with hyperchloremia (chloride ≥113 mmol/L), regardless of AKI status. Without considering baseline chloride, sodium bicarbonate therapy was not associated with a mortality benefit in patients with moderate to severe AKI.
METHODS: A retrospective cohort of children with metabolic acidosis was selected from the Paediatric Intensive Care (PIC) database. Intensive care unit (ICU)-related data on diagnosis, laboratory tests, treatment, and outcomes were retrieved. Sub-grouping was done based on AKI status and baseline chloride levels. In-hospital and 28-day mortality were compared between children receiving and not receiving sodium bicarbonate, with adjustment for confounding factors.
RESULTS: Sodium bicarbonate therapy did not decrease in-hospital or 28-day mortality in overall AKI or in overall non-AKI children. Among stage 2-3 AKI [pediatric reference change value optimized for AKI (pROCK)] children, those on therapy had lower in-hospital (19.43% vs. 35.40%, P=0.002) and 28-day (17.43% vs. 32.74%, P=0.002) mortality, but this was not significant after adjustment. Stratification by baseline chloride level revealed a divergent association: when chloride was ≥113 mmol/L, sodium bicarbonate therapy was associated with lower mortality in both AKI and non-AKI children; conversely, when chloride was <107 mmol/L, it was associated with increased mortality.
CONCLUSIONS: The association between sodium bicarbonate therapy and mortality in children with metabolic acidosis critically depends on baseline chloride levels. Its use was associated with increased mortality in those with hypochloremia (chloride <107 mmol/L) but reduced mortality in those with hyperchloremia (chloride ≥113 mmol/L), regardless of AKI status. Without considering baseline chloride, sodium bicarbonate therapy was not associated with a mortality benefit in patients with moderate to severe AKI.